Stock comparison
Alvotech
IDEXX Laboratories
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALVO
Alvotech
Market cap
$1.04B
Sector
Healthcare
IDXX
IDEXX Laboratories
Market cap
$44.12B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALVO | IDXX | Winner |
|---|---|---|---|
| Warren Buffett | 44D | 75B | IDXX |
| Benjamin Graham | 51D | 80A | IDXX |
| Philip Fisher | 55C | 75B | IDXX |
| Peter Lynch | 78C | 71B | ALVO |
| Joel Greenblatt | 45D | 83C | IDXX |
| Charlie Munger | 52D | 87A | IDXX |
| Terry Smith | 43D | 84A | IDXX |
Side-by-side metrics
| Metric | ALVO | IDXX |
|---|---|---|
| Market cap | $1.04B | $44.12B |
| P/E (TTM) | 33.1x | 39.0x |
| EV/EBIT | 29.5x | 31.6x |
| ROIC (TTM) | 1.3% | 40.66% |
| Gross margin | 59.82% | 62.05% |
| Net margin | 4.76% | 24.63% |
| Revenue CAGR 5y | 99.83% | 7.56% |
| EPS CAGR 5y | - | 10.79% |
| Debt / Equity | - | 0.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALVO leads on
- Debt / Equity-vs 0.7x+114%
- Revenue CAGR 5y99.83%vs 7.56%+92%
- P/E (TTM)33.1xvs 39.0x+15%
- EV/EBIT29.5xvs 31.6x+7%
IDXX leads on
- Market cap$44.12Bvs $1.04B+98%
- ROIC (TTM)40.66%vs 1.3%+97%
- Net margin24.63%vs 4.76%+81%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.